甲磺酸伊马替尼临床研究概况  

The Advances in Clinical Study of Imatinib Mesilate

作　　者：郑斌[1] 危晴岚[1] 刘茂柏[1] 

机构地区：[1]福建医科大学附属协和医院,福州350001

出　　处：《海峡药学》2006年第6期78-80,共3页Strait Pharmaceutical Journal

摘　　要：甲磺酸伊马替尼是一种蛋白质酪氨酸激酶抑制剂,用于治疗Ph染色体阳性慢性粒细胞白血病和恶性胃肠道间质肿瘤。本文从耐药机制、不良反应、生活质量考察、药物经济学成本-效用分析等方面综述了其最新临床研究进展。Imatinib mesilate is a protein-tyrosine kinase inhibitor approved for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia and malignant gastrointestinal stromal tumors. In this article we reviewed the advances in clinical study of imatinib including its mechanism of resistance,adverse events,life quality study and cost-effective analysis ,etc.

关 键 词：甲磺酸伊马替尼 慢性粗细胞白血病 耐药机制 不良反应 

分 类 号：R969.4[医药卫生—药理学]